Trending NewsTrending NewsNASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $36.79 +23.02 (+167.18%) Closing price 07/28/2025 04:00 PM EasternExtended Trading$36.57 -0.22 (-0.60%) As of 07/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celcuity Stock (NASDAQ:CELC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celcuity alerts:Sign Up Key Stats Today's Range$35.00▼$46.4250-Day Range$10.44▼$36.7952-Week Range$7.57▼$46.42Volume27.59 million shsAverage Volume283,091 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$39.20Consensus RatingBuy Company Overview Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Read More Celcuity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreCELC MarketRank™: Celcuity scored higher than 12% of companies evaluated by MarketBeat, and ranked 896th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCelcuity has only been the subject of 4 research reports in the past 90 days.Read more about Celcuity's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.62) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 11.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.56% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Celcuity has recently decreased by 1.23%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.56% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Celcuity has recently decreased by 1.23%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.11 News SentimentCelcuity has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Celcuity this week, compared to 3 articles on an average week.Search Interest7 people have searched for CELC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have not sold or bought any company stock.Percentage Held by Insiders15.78% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELC Stock News HeadlinesWhy Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket3 hours ago | benzinga.comCelcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial3 hours ago | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Celcuity Shares Double After Landmark Breast Cancer Drug Trial Results3 hours ago | msn.comCelcuity Stock Triples on Positive Breast Cancer Treatment Study3 hours ago | msn.comCelcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common StockJuly 28 at 4:02 PM | globenewswire.comCelcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in studyJuly 28 at 8:03 AM | reuters.comCelcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 TrialJuly 28 at 7:00 AM | globenewswire.comSee More Headlines CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $13.09 at the start of the year. Since then, CELC shares have increased by 181.1% and is now trading at $36.79. How were Celcuity's earnings last quarter? Celcuity, Inc. (NASDAQ:CELC) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.09. Read the conference call transcript. When did Celcuity IPO? Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2025Today7/29/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Celcuity$39.20 High Price Target$60.00 Low Price Target$27.00 Potential Upside/Downside+6.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-96.21% Return on Assets-49.44% Debt Debt-to-Equity Ratio1.14 Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book11.83Miscellaneous Outstanding Shares37,870,000Free Float31,891,000Market Cap$1.39 billion OptionableOptionable Beta0.45 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CELC) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.